- Home
- FNWB vs CGTX Comparison
FNWB vs CGTX Comparison
Compare FNWB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWB | CGTX |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 94.5M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FNWB | CGTX |
|---|---|---|
| Price | $9.13 | $1.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $3.33 |
| AVG Volume (30 Days) | 27.4K | ★ 678.0K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.22 |
| 52 Week High | $10.98 | $3.83 |
Technical Indicators
Market Signals| Indicator | FNWB | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 41.38 |
| Support Level | $7.56 | $1.00 |
| Resistance Level | $9.50 | $1.04 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 5.86 | 18.42 |
Price Performance
Historical ComparisonAbout FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.